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Abstract: Neuropathic pain constitutes a significant portion of chronic pain. Patients with 
neuropathic pain are usually more heavily burdened than patients with nociceptive pain. They 
suffer more often from insomnia, anxiety, and depression. Moreover, analgesic medication often 
has an insufficient effect on neuropathic pain. Spinal cord stimulation constitutes a therapy 
alternative that, to date, remains underused. In the last 10 to 15 years, it has undergone constant 
technical advancement. This review gives an overview of the present practice of spinal cord 
stimulation for chronic neuropathic pain and current developments such as high-frequency 
stimulation and peripheral nerve field stimulation.
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Introduction
Neuropathic pain constitutes a significant portion of chronic pain. The International 
Association for the Study of Pain defines neuropathic pain as pain caused by a lesion 
or disease of the somatosensory nervous system. Patients with neuropathic pain usu-
ally are more heavily burdened than patients with nociceptive pain and suffer more 
often from insomnia, anxiety, and depression.1 Moreover, analgetic medication often 
has an insufficient effect on neuropathic pain.2
Spinal cord stimulation (SCS) constitutes a therapy alternative that, to date, remains 
underused.3,4 It was described for the first time in 1967 and has become a standard 
therapy in many hospitals since the middle of the 1980s. Nonetheless, there is still 
a significant underuse of this treatment. In the last 10–15 years, SCS has undergone 
constant technical advancement. Stimulation patterns can now be adjusted according 
to the patient’s needs, thus increasing the efficacy of stimulation.
SCS for the treatment of pain must be seen in the general context of neuromodulative 
therapies. Neuromodulation has undergone rapid development in the last few years. 
Today, neurostimulation systems are used not only in the therapy of chronic pain but 
also in a multitude of different disorders, such as epilepsy, psychiatric diseases, and 
movement disorders, as well as gastrointestinal and urological diseases. This review 
gives an overview of the present practice of SCS for chronic neuropathic pain and 
current developments in the field.
Outline of the history of SCS and its uses
The development of SCS was one of the consequences of the gate control theory of 
Melzack and Wall.5 They stated that external and internal pain stimuli are recorded Journal of Pain Research 2014:7 submit your manuscript | www.dovepress.com
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by pain receptors in the skin, muscles, joints, and internal 
organs and switched to the second neuron of the pain path-
way within the dorsal horn of the spinal cord. Here, many 
peripheral neurons converge to a single neuron termed the 
wide dynamic range neuron. According to their theory, activa-
tion of myelinated Aβ fibers inhibits pain transmission and 
is enhanced by activation of thinly myelinated Aδ fibers and 
unmyelinated C fibers.5
Shealy et al employed SCS in 1967 for the first time 
in an animal model, using a technique that they termed 
dorsal   column stimulation at that time. They showed 
that dorsal   column stimulation, as well as stimulation of 
the anterior spinocerebellar tract, inhibited paw withdrawal 
after painful stimuli in cats.6 In the same year, they treated a 
patient who suffered from intractable pain resulting from a 
progressive-state inoperable bronchial carcinoma. Electrode 
implantation was performed over a thoracic laminectomy at 
the level TH 2/3. After starting the stimulation, pain was dras-
tically reduced and analgetic medication could be stopped. 
The patient died after 6 days from a previously undetected 
bacterial endocarditis.7 In 1970, Shealy et al published a series 
of six patients with various diagnoses who had been treated 
with SCS; three of them had a very good outcome.8
Nashold and Friedman published the first larger study on 
SCS in 1972. In this study, patients with neuropathic pain 
responded better to stimulation than patients with nociceptive 
pain such as bone pain, joint pain, and discal pain.9 The same 
year, a two-step procedure with percutaneous testing of the 
electrode before final implantation of the impulse generator 
was proposed by Hosobuchi et al.10 A study of 50 patients 
published in 1974 showed that SCS led to better results in 
phantom pain than in peripheral nerve lesions.11 Before 
1980, intra- or subdural electrodes were often employed,12 
sometimes leading to grave complications such as intraspinal 
bleeding13 or spinal cord damage.14 Therefore, great caution 
is required in comparing the treatment data from that time 
with those of our time.
Mechanisms of action
The first explanation of the effects of SCS according to the 
gate control theory was that the nociceptive signal in the 
dorsal horn would be inhibited by antidromic activation 
of collateral fibers of the dorsal columns. This explanation 
later turned out to be only partially true. According to this 
explanation, acute nociceptive pain would be inhibited most 
effectively by SCS, which in fact is not the case. In addi-
tion, the pain-free interval after cessation of stimulation 
cannot be explained in that way. Apparently, there is also 
an   orthodromic stimulation, which becomes manifest in the 
paresthesia felt by the patient under stimulation. Supraspinal 
centers are also involved in SCS effects.15 At the time the 
gate control theory was first described, there was only a little 
knowledge about supraspinal control of pain transmission, 
and SCS was thought to act at the segmental level.16
In animal models, a couple of possible mechanisms 
of action have been described. Overexcitability of wide 
dynamic range (WDR) neurons in the dorsal horn can at 
least partially be overcome by SCS.17 This seems to be 
related to an increased basal release of glutamate and to a 
dysfunction of the γ-amino-butyric acid (GABA) system. 
SCS counteracts this mechanism by increased GABA release. 
However, GABA release was only observed in animals that 
also had pain relief effected by SCS.18 Moreover, SCS led 
to a decreased extracellular glutamate concentration in the 
dorsal horn.19 Here, activation of the GABAB receptor seems 
to play a crucial role.19–21 Cholinergic transmitter systems are 
also involved in SCS effects. Release of acetylcholine was 
observed under SCS and later attributed to activation of the 
M4 muscarine receptor.22 Moreover, low doses of muscarine 
receptor agonists led to amplification of the SCS effects in 
rats,23 and it was shown that serotonergic pain-modulating 
descending pathways were involved in this effect.24
Moreover, supraspinal centers are also engaged in 
the effect of SCS. Here, in particular, a dorsal column–
brainstem–spinal loop is of importance.25–27 Barchini et al 
recently addressed the question of the relative proportions of 
supraspinal and segmental mechanisms in SCS effects. They 
studied the effect of SCS on neuropathic pain after lesioning 
the dorsal columns and stimulating rostral and caudal to the 
lesion under the influence of different receptor antagonists. 
They found that segmental as well as supraspinal mechanisms 
contribute to the effects of SCS and that stimulation rostral 
and caudal to the lesion leads to activation of different syn-
aptic circuits and transmitter systems.16
The question of how stimulation of the spinal ganglia and 
SCS differ clinically and electrophysiologically was studied 
by Guan et al28 by means of single-cell electrodes in WDR 
neurons. They found that SCS inhibited wind-up in the WDR 
neurons, whereas stimulation of the spinal ganglia did not. 
The effect of SCS continued, at least partially, for about 
30–45 minutes after cessation of the stimulation.28
Patient selection/screening, 
including psychological
SCS can have diverging clinical effects in different patients. 
It has been known for many years that some patients do Journal of Pain Research 2014:7 submit your manuscript | www.dovepress.com
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not profit from SCS, but others do. Therefore, a two-step 
  procedure with a test phase before implantation of the 
impulse generator (IPG) has become routine in most hospitals 
since the 1970s. It has become apparent that about 17%–20% 
of the patients have a negative trial result29 and do not proceed 
to IPG implantation, even when the test electrode has the 
optimal position and the paraesthesia coverage of the pain-
ful region is complete. Moreover, SCS effects diminish over 
time after IPG implantation in some patients. The extent of 
decrease of SCS effect over time is reported variously in the 
literature. Some studies state that the effect has decreased 
25%–50% after 2 years,30 but others only see a slight loss of 
efficacy over time.31 Often technical factors such as electrode 
problems (dislocation, breakage) have been cited to explain 
the loss of efficiency. However, psychological factors also 
come into account with regard to both the loss of efficacy 
over time and a negative trial result.
Several guidelines recommend that psychological testing 
should be performed before SCS implant. The first aim of this 
testing is to rule out major psychiatric diseases such as major 
depression, psychosis, or substance abuse. There is a vast 
consensus that patients with these diagnoses should not be 
subjected to SCS testing. However, it remains to be determined 
whether there are also psychological factors below the level of 
severe pathology, which can negatively influence SCS efficacy. 
Regarding this question, the literature remains somewhat incon-
clusive; regarding the long-term efficiency, there are studies that 
find a negative correlation between the level of depression and 
SCS efficacy,32,33 whereas others do not.30,33
In contrast, the level of depression remains one of the 
functional items that can show remarkable improvements 
after SCS implantation. Thus, even if SCS efficacy might 
be slightly lower in patients with mild depression, IPG 
implantation might be justified because apart from pain relief, 
depression can also improve under SCS.31
Pre- and postimplant  
advice to patients
Preoperatively, the indication should be considered cau-
tiously, taking the prior conservative medical physio-
therapeutic and psychotherapeutic approaches into account. 
Differential diagnosis also requires determining the propor-
tions of nociceptive and neuropathic pain; for instance, 
by means of diagnostic nerve root blocks. SCS should be 
considered when the radicular (neuropathic) part of the pain 
outweighs the nociceptive portion (Figure 1).
Some guidelines, moreover, claim interdisciplinary 
decision-making before testing SCS. At least a   psychological 
examination should be carried out before SCS implantation 
in any case. The psychological examination should not 
only contribute to decision-making about whether or not to 
implant the electrode, but should also prepare the patient for 
the postoperative course and render it easier for the patient 
to deal with having an implantable device.
Electrode implantation usually is performed under local 
anaesthesia, using percutaneous-type electrodes, which can 
be inserted under fluoroscopic guidance. First, the spinal 
canal is punctured with a Touhy needle. Once the spinal 
canal is reached, intraspinal localization of the needle tip 
is ensured by means of a saline probe, a technique that can 
be strongly recommended to ensure the safety of the pro-
cedure and to prevent cerebrospinal fluid leaks. Then, the 
electrode is advanced to the desired level. In the case of leg 
pain, the usual electrode position is TH10–12 (Figure 2). In 
thoracic pain (such as postherpetic neuralgia), the electrode 
position depends on the level of the pathology, and in brachial 
pain, final electrode position is at level C3–C6 (Figure 3). 
Once the electrode is in the desired position, intraoperative 
test simulation is performed and the patient is asked to state 
where he feels the stimulation-induced paresthesia. At this 
stage, it is most important to obtain full paresthesia coverage 
of the painful area. Sometimes the electrode position must be 
changed before the optimal paraesthesia is achieved.
The patient then proceeds to a test phase, which usually 
lasts about 6–12 days. Some hospitals also prefer testing 
under domestic circumstances. Mostly, however, testing is 
performed in the hospital. The patient is asked to document 
his or her pain scores during the test phase. The decision 
whether or not to implant an IPG is dependent on whether 
or not more than 50% pain reduction is obtained, whether 
quality of life and moods are improved, whether analgetic 
medication can be reduced, and whether the patient wants 
the implant.
After implantation of the IPG, reprogramming of the 
device often is needed one or more times. Patients should be 
informed that slight changes in the SCS-induced paresthesia 
can occur and that these can be relieved by reprogramming the 
device. Patients often ask whether they should avoid physical 
activities to avoid electrode dislocation. In our experience, the 
risk for electrode dislocation is highest in the first few weeks 
after implantation, so we would not recommend heavy lifting 
or intense bending of the spine in this stage. After implan-
tation of the IPG, the analgetic medication should also be 
reconsidered and possibly stopped. The patient can also better 
determine over time which simulation pattern, intermittent or 
continuous, is most suitable in his situation.34Journal of Pain Research 2014:7 submit your manuscript | www.dovepress.com
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Current technological 
developments
Burst stimulation
One new development in SCS refers to the order and fre-
quency of impulses. De Ridder et al35 published a series 
of 12 patients who had been treated by means of a “burst 
stimulation”. This pattern of stimulation consists in so-
called “bursts” of 5 impulses of 1 ms duration followed by 
a 1 ms interval, applied at a frequency of 500 Hz. These 
5-impulse “bursts” are applied at 40 Hz. Under this stimula-
tion pattern, pain was strongly relieved compared with using 
conventional stimulation. Moreover, no stimulation-induced 
Lead insertion in local
anaesthesia  
Trial stimulation  
If negative: removal of 
electrode,
conservative treatment    
Decision to implant impulse generator,
based on: pain scores, medication use,
quality of life, patient satisfaction   
Programming (eventually
reprogramming), reduction of
medication   
If positive: Impulse generator implantion
(general anesthesia)  
Documentation of effect: pain
scores, medication use  
Anamnesis, clinical examination 
Interdisciplinary evaluation
(including psychological)  
Figure 1 Flow chart of spinal cord stimulation procedure.
Figure  2  Anteroposterior  and  lateral  view  of  a  thoracolumbar  spinal  cord 
stimulation placement; the 8-pole lead (octrode) is positioned at level TH10–12, and 
the impulse generator is placed abdominally subcutaneously.
Abbreviations: R, right; L, left.Journal of Pain Research 2014:7 submit your manuscript | www.dovepress.com
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paresthesia was necessary to obtain a pain-relieving effect. 
Furthermore, unlike “conventional” SCS, not only leg pain 
but also back pain was relieved.35,36
High-frequency stimulation
Recently, a prospective multicenter study on high-frequency 
SCS (continuous stimulation with 10 kHz) showed favorable 
results.37 In this new technique, two octrodes are implanted 
in a staggered manner at level TH8 down to TH12. It has 
been observed that not only radicular leg pain but also back 
pain can be treated in this way. Eighty-two patients were 
treated in the study. An IPG was implanted in 72 patients. 
The mean intensity of back pain decreased from 8.2 to 2.7 
on the visual analog scale and the mean intensity of the leg 
pain decreased from 5.4 to 1.4. The results also remained 
stable after 24 months.38 One peculiarity of this stimulation 
technique is that no paresthesia is perceived by the patient. 
The effectivity of high-frequency stimulation was explained 
by desensitization of hyperactive WDR neurons and with 
control of the wind-up phenomenon of WDR neurons. 
However, no experimental evidence for this assumption was 
provided.37 Moreover, a randomized study that compared 
a 5 kHz stimulation with a sham stimulation in a blinded 
manner did not find significant differences between the two 
stimulation techniques.39
At the present stage, it is probably too early to draw 
final conclusions on the pain-relieving efficiency of high-
frequency stimulation. However, as long as there is no clear 
neurophysiological hypothesis explaining the intense effect 
and the paresthesia-free pain relief, some reservation toward 
this new method might be indicated.
Position-adaptive SCS
The intensity of the SCS-induced paresthesia is dependent 
on body position.40–42 Under equal technical settings of the 
stimulator, the paresthesia is perceived more intensely in the 
supine position than in an upright position. Therefore, up to 
now, patients had to correct changes in stimulation intensity (ie, 
while standing up) by means of a handheld programming device. 
This position dependency of the stimulation is not caused by a 
dislocation of the electrode. In fact, it is based on the variable 
thickness of the cerebrospinal fluid layer around the spinal cord. 
Holsheimer et al43 pointed out that the position of the spinal cord 
within the spinal canal exhibited considerable interindividual 
differences. By means of a computer model, they calculated the 
expected thresholds for stimulation on the basis of anatomical 
and radiological data. The calculated data corresponded to the 
thresholds measured in individual patients.43 Likewise, Abejon 
and Feler44 found that the impedance of the electrode is not 
dependent on the body position. Thus, changes in body position 
do not interfere with changes in the electrical conductivity of 
the electrode and the directly adjacent tissues.44,45
Recently, new position-adaptive stimulation devices have 
been introduced. These devices are able to detect whether the 
patient is lying down or standing. The stimulation intensity 
is then automatically fitted to previously set values. With this 
technique, there is no longer any need for the patient to adjust 
the stimulation intensity after changing his position.
A study with 15 patients showed that patients with 
automatic sensor-driven stimulation were significantly more 
satisfied than with manually adapted stimulation.46 A recent 
multicenter study with 79 patients showed functional improve-
ments; in particular, enhanced comfort during position 
changes, increased physical activity, and improved sleep.47
Novel peripheral neurostimulation 
techniques
Two new developments of neurostimulation are addressed 
here that actually do not constitute a type of SCS, as the 
peripheral nerves or the dorsal root ganglion are stimulated 
rather than the spinal cord. However, these techniques share 
most of the indications and use much of the same hardware. 
Therefore, they should be mentioned in the context of SCS.
Peripheral nerve field stimulation
Stimulation of a single peripheral nerve has been employed 
for more than 30 years in pain treatment.48 With this tech-
nique, the affected peripheral nerve (ie, N. ulnaris) is exposed 
and an electrode (ie, a cuff-electrode) is placed directly 
adjacent to the nerve. Alternatively, a percutaneous-type 
electrode can be inserted under the epineurium.49
Figure 3 Anteroposterior and lateral view of a cervical spinal cord stimulation 
placement; the 8-pole lead (octrode) is positioned at level C3-5, and the spinal canal 
is entered at level TH2/3.
Abbreviation: R, right.Journal of Pain Research 2014:7 submit your manuscript | www.dovepress.com
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Peripheral nerve field stimulation (PNFS) is a different 
method. Here the electrode is placed subcutaneously, with 
no direct relation to a particular peripheral nerve. One of 
the first applications of this method was occipital nerve 
stimulation (ONS) for chronic migraine50 or chronic cluster 
headache.51–54 Here, however, there are different opinions 
about whether ONS is a peripheral nerve stimulation or a 
PNFS. In fact, the electrode is mostly placed adjacent to the 
occipital nerve in ONS, but as this is not done under visual 
control, this ONS is probably a form of PNFS rather than 
peripheral nerve stimulation.55
PNFS in a way closes a therapeutic gap in neuromodula-
tive pain treatment, as it can possibly reach the trunk more 
effectively than SCS. First publications on PNFS dealt with 
chronic abdominal pain.56,57 Later, studies concerning chronic 
thoracic pain,58,59 chronic low back pain,60–63 failed back sur-
gery syndrome (FBSS),64,65 and sacroiliac joint pain66 also 
were published.
PNFS has been described in a couple of case reports,58,59,67 
smaller cases series,56,62,65 and some studies with higher 
case numbers.61,64,68 A retrospective multicentre study on 
111 patients with chronic low back pain, FBSS, cervical pain, 
postherpetic neuralgia, tension headache, and some patients 
with trigeminal neuralgia or thoracic pain showed that the 
relatively best pain relief was obtained in patients with 
thoracic back pain, whereas the least pain relief was seen in 
patients with tension headache. Pain scores in total decreased 
from 8.2 without stimulation to 4.0 with stimulation. The 
mean medication use was significantly reduced.69 A recent 
prospective multicenter study on 118 patients of PFNS on 
chronic low back pain showed similar results.70
Interestingly, pain relief by TENS does not seem to be a 
predictor for the success of PFNS,71 and pain relief elicited 
by PNFS seems to be stronger than in TENS.69 A so-called 
“hybrid simulation”, combining SCS and PFNS, has also 
been proposed for various pain syndromes.61,62,65,67,72–74
A randomized study on PFNS showed that the stimulation 
under standard settings is significantly more effective than 
at subthreshold intensity or low frequency.75
The advantages of PNFS are that it is less invasive and 
that it offers the opportunity to treat the pain syndromes that 
cannot be treated with SCS. Some pain syndromes, such 
as postherpetic neuralgia, can be treated by both PFNS 
and SCS, and it remains to be determined which of the two 
techniques offers the higher efficiency. The comparison of 
the effects of SCS and TENS, as a peripheral stimulation, 
on evoked potentials showed that the SCS effect was nearly 
twice as strong as that of TENS.76
Dorsal root ganglion stimulation
In this technique, the electrode is placed directly adjacent to 
the spinal ganglion. With one electrode, paresthesia is only 
achieved within a single dermatome. Greater pain areas can 
be covered with the use of more than one electrode. The 
implantation technique is more challenging than that of SCS. 
A pilot study on 10 patients showed a mean pain relief of 
70% in the first days after implantation. Energy consumption 
with this technique seems to be significantly less compared 
with SCS.77 A recent multicenter study on 32 patients with 
a 6-month follow-up showed a mean pain relief of 58%. As 
expected, mean pain relief was strongest in the feet and weak-
est in the low back.78 A series of eight patients with complex 
regional pain syndrome (CRPS) showed a decrease of mean 
pain scores of 62% under dorsal root ganglion stimulation.79 
Dorsal root ganglion stimulation can be considered particu-
larly in monoradicular pain syndromes or pain syndromes 
affecting a very limited number of dermatomes.
Indications
In general, SCS is indicated in refractory neuropathic pain 
(Table 1). Early experiences have suggested that SCS is less 
effective in nociceptive pain. Nonetheless, in some cases it 
might be difficult to differentiate between the neuropathic and 
the nociceptive components of pain, and an SCS trial can be 
justified even if there are also nociceptive components in the 
pain syndrome. The most frequent and best studied indication 
is radicular pain secondary to lumbar disc surgery (FBSS). 
According to a recent review, FBSS evolves in approximately 
30% of patients after lumbar disc surgery.80 Two randomized 
controlled trials and numerous retrospective studies have 
been published for FBSS. In a crossover design, North et al81 
studied 50 patients with FBSS who had either SCS or a revi-
sion operation. Forty-five persons were followed for 3 years. 
Nine of 19 patients with SCS and three of 26 patients with 
the reoperation had more than 50% pain relief. In the SCS 
group, the crossover rate was lower than in the reoperation 
group (5/24 versus 14/26).81 A study on 100 patients with 
FBSS and predominantly neuropathic leg pain was con-
ducted by Kumar et al.82 They randomized the patients into 
two groups; one group had conventional analgetic therapy 
alone and the other group had conventional analgetic plus 
SCS. The earliest time for a crossover was 6 months. At that 
time, 48% of the patients who had been treated with SCS 
had more than 50% pain relief, whereas this was the case in 
the conservative treatment group in only 9% of the patients. 
Again, the crossover rate was significantly lower in the SCS 
group than in the conservative group (5/50 versus 32/50).82 Journal of Pain Research 2014:7 submit your manuscript | www.dovepress.com
Dovepress 
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Several guidelines recommend a trial of SCS in FBSS. A 
systematic review found class IIb evidence for efficacy of 
SCS in FBSS.83
Another good and well-studied indication for SCS is 
CRPS (CRPS I and II). In this potentially devastating neuro-
orthopedic pain syndrome the use of SCS has been studied in 
several observational studies and one randomized controlled 
trial. In this study, the effectivity of SCS combined with a 
6-month physiotherapeutic treatment protocol was compared 
with a physiotherapeutic treatment protocol alone. Thirty-six 
patients were included in the SCS group, whereas 18 patients 
had solely physiotherapeutic treatment. Test stimulation was 
successful in 24 of the 36 patients. Patients in the SCS group 
had a mean pain relief of 2.4 points (on an 11-point scale), 
whereas patients with solely physiotherapeutic treatment had 
pain relief of 0.2 points. These differences were statistically 
significant and remained stable after 1 and 2 years.84 After 3 and 
5 years, however, significant differences in the treatment groups 
were no longer seen. In these studies, as in the primary study, 
an intention-to-treat analysis was carried out that included the 
12 patients with the negative trial in the SCS group. More-
over, four patients in the control group had received an SCS 
system.85,86 Interestingly, a study by Harke et al87 had a kind of 
internal control. This internal control, in which the stimulator 
was switched off for 45 minutes, was performed every 3 months 
during the 35-month follow-up. Pain scores for depth pain and 
allodynia during these inactivity tests were 7.1/10 and 4.0/10, 
respectively. Under stimulation, these scores decreased to 
1.7/10 and 0.03/10, respectively.87 in addition to these studies, 
several case series regarding the use of SCS for the treatment of 
CRPS have been published. A meta-analysis showed that 67% 
of the patients experienced pain relief of more than 50%.88
SCS has also been successfully employed in a number 
of neuropathic pain syndromes. Excellent results have 
been achieved in the treatment of postherpetic neuralgia. In 
23/28 patients, pain relief from a median 9/10 on the visual 
analog scale to 1/10 was achieved. Complete pain relief was 
observed in 23 of 28 patients (82%) after 3–66 months.89 
Moreover, postherpetic neuralgia has been studied in 
a number of larger studies with miscellaneous indica-
tions.90–92 A meta-analysis showed a success rate of 82%.93 
Interestingly, SCS has also been proposed as a short-term 
therapy for subacute herpes zoster or beginning postherpetic 
neuralgia. Here, a 14-day short-term therapy with an exter-
nalized electrode led to complete and lasting pain relief in 
some patients.94,95
One indication for SCS that is not yet general practice 
is diabetic polyneuropathy. In 1996, a case series was pub-
lished in which 8 of 10 patients tested were treated with SCS. 
Mean pain scores decreased in these patients from 7.7/10 
to 2.3/10. However, pallhypesthesia and electrophysio  logical 
tests remained unchanged.96 A systematic review of SCS for 
diabetic polyneuropathy lists three prospective case series 
and one retrospective cohort study. At 1-year follow-up, 
63% of the patients had more than 50% pain reduction. In 
addition, analgetic medication could be stopped in 60% of 
the patients.97 Recently, long-term effects for SCS for diabetic 
polyneuropathy were shown over a follow-up of 3 years.98
Successful pain treatment with SCS has been described 
in a single case report in a vast variety of neuropathic pain 
syndromes such as syringomyelia,99 post-thoracotomy neu-
ralgia,100 recurrent neuroma,101 tethered cord syndrome,102 
  meralgia paresthetica,103 or even multiple sclerosis.104 
  Favorable outcomes have also been reported in mixed pain 
syndromes regarding shoulder pain105 and knee pain.106
Table 1 Overview of indications and contraindications for spinal 
cord stimulation
Indications and contraindications
indications
  Neuropathic pain
      Failed back surgery syndrome 
Complex regional pain syndrome (type i and ii) 
Radicular pain 
Nerve root pain (lumbar, thoracic, cervical) 
Radiculopathy, radiculitis 
Postherpetic neuralgia 
Neuropathic pain secondary to peripheral nerve injury 
intercostal neuralgia 
Phantom pain
  vascular pain
      Angina pectoris 
Peripheral arterial disease 
Morbus raynaud
  Potential indications
      Polyneuropathy 
Deafferentation pain 
Spinal cord injury 
Brachial plexus injury
Contraindications
  Somatic
      Sepsis 
Coagulopathy 
infection 
inability to understand how SCS works and to handle the patients 
Programming device 
Obliteration of the spinal canal
  Psychiatric
      Psychosis 
Schizophrenia 
Substance abuse 
Severe depression/anxiety
Abbreviation: SCS, spinal cord stimulation.Journal of Pain Research 2014:7 submit your manuscript | www.dovepress.com
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Table 2 Overview of randomized studies for SCS (and PNFS)
Title/author Year Diagnosis Condition Design n Result
Conventional SCS
    PROCeSS, 
Kumar  
et al82,107
2005 Failed back surgery 
syndrome
SCS plus CMM vs CMM 
alone
Randomized prospective, 
multicenter
100 48% of the SCS patients had more 
than 50% pain relief compared with 
9% with CMM, cross-over-rate 
was significantly lower in the SCS 
group than in the CMM group 
(5/50 vs 32/50)
    North  
et al81,108,109
1994 Failed back surgery 
syndrome
SCS plus CMM vs 
reoperation plus CMM
Randomized prospective, 
multicenter
60 9/19 patients with SCS and 
3/26 patients with reoperation 
had more than 50% pain relief; in 
the SCS group, the crossover rate 
was lower than in the reoperation 
group (5/24 vs 14/26)
    Kemler  
et al84,85,110
2000 Complex regional pain 
syndrome type i
SCS plus physical therapy 
vs physical therapy
Randomized prospective, 
multicenter
54 24/36 patients had a successful test 
and were implanted, mean change 
in pain at 6 months; 2.4 vAS with 
SCS vs; 0.2 vAS without SCS
Subthreshold stimulation
    wolter et al1112011 Neuropathic pain SCS vs subthreshold SCS 
vs no stimulation
Randomized prospective, 
crossover design
10 SCS: mean vAS, 3.6; subthreshold: 
5.6; no stimulation: 6.4; differences 
significant
Adaptive stimulation
    Schultz et al47 2012 Neuropathic back and 
leg pain
Conventional SCS vs 
position adaptive SCS
Randomized prospective, 
multicenter crossover 
design
79 improved convenience of adaptive 
stimulation compared with using 
manual programming adjustment 
alone
    Schade et al46 2011 Neuropathic back and 
leg pain
Conventional SCS vs 
position adaptive SCS
Randomized prospective, 
multicenter crossover 
design
15 improved convenience and overall 
satisfaction of adaptive stimulation
High-frequency stimulation
    Perruchoud 
et al39
2013 Neuropathic back and 
leg pain
HF SCS vs SCS vs sham Randomized prospective, 
crossover design
33 Switched from conventional SCS to 
5 kHz SCS or to sham, vAS levels 
remained stable; authors concluded 
that HF SCS was equivalent to sham
Burst stimulation
    De Ridder  
et al36
2013 Neuropathic back and 
leg pain
Burst vs tonic vs placebo Randomized prospective, 
crossover design
15 Burst stimulation improved back, 
limb, and general pain by 51%, 53%, 
and 55% and tonic stimulation by 
30%, 52%, and 31%
PNFS
    McRoberts 
et al75
2013 Localized, chronic, 
intractable back pain
PNFS Randomized prospective, 
multicenter crossover 
design
44 23 patients responded to 
stimulation (,50% pain reduction) 
and received impulse generators
Abbreviations: SCS, spinal cord stimulation; PNFS, peripheral nerve field stimulation; CMM, conventional medical management; HF SCS, high-frequency SCS; VAS, visual 
analog scale; vs, versus.
An overview of randomized controlled studies is given 
in Table 2.36,39,46,47,75,81,82,84,85,107–111
Safety
SCS can be considered a safe technique. The probability 
of sustaining permanent damage caused by an SCS trial is 
extremely low. The puncture of the spinal canal comprises the 
inherent risk of spinal bleeding and permanent neurological 
deficit; however, the literature lists only six reported cases of 
neurological deficits resulting from damage of the spinal cord. 
In 2010, Smith et al reported a series of four patients with para-
paresis occurring after a spinal cord stimulator trial.112 Two of 
these patients had spinal bleeding, one patient had spinal cord 
injury, and in one patient a preexisting thoracic disc herniation 
was encountered. To rule out thoracic disc herniation or spinal 
stenosis, the authors advocated magnetic resonance imaging 
(MRI) before SCS lead insertion. In the same article, the authors 
quoted two additional cases of paraparesis secondary to SCS Journal of Pain Research 2014:7 submit your manuscript | www.dovepress.com
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lead insertion: one case of dural puncture and intramedullary 
lead placement113 and another case of needle penetration in the 
cervical cord.114 However, neurological deficit developing in the 
course of time, as a consequence of scarring,115–117 of an epidural 
mass,118 or of a foreign body reaction119 has also been reported 
in case reports. Given the fact that several hundred thousand 
SCS devices have been implanted worldwide since its advent, 
even admitting that neurological deficits after SCS might be 
underreported, this hints at a low probability of permanent 
neurologic deficit to SCS electrode implantation.
Infection can occur after SCS implantation. The incidence 
is reported between 3.4%92 and 6%.120 Usually, cases of infec-
tion have an uneventful benign course when the electrodes 
are removed and antibiotic therapy is initiated.
The probability of unscheduled additional revision 
operations caused by hardware problems, such as lead dis-
location or lead breakage, is apparently high. A systematic 
review of SCS for FBSS or chronic back and leg pain found 
that 43% of the patients had one or more complications with 
SCS. Most of these were lead problems (lead dislocation). 
  Infections were encountered in 6% of the patients and 
  cerebral spinal fluid leaks in 7%.120 A monocentric study 
on 707 patients found no patient with permanent neurologic 
deficit.   However, hardware failures in this series occurred 
in 38% of the patients (22.6% lead migration, 9.5% lead 
connection failure, and 6% lead breakage).121 Another large 
study on hardware failure modes found a significantly higher 
revision rate in cervical than in thoracolumbar SCS systems. 
Again, lead migration was the most frequent cause of repeat 
surgery122 (Table 3).
The use of paddle leads that have to be implanted surgi-
cally via laminotomy has been advocated for patients with a 
history of lead migration. A recent study showed that the ini-
tial complication rate was higher with paddle leads compared 
with percutaneous leads, but the longer-term reoperation rate 
was significantly lower.123
Interaction of SCS with diathermy, cardiac pacemakers, 
ultrasound, or MRI is possible and can lead to unwanted 
paresthesia or dysfunction of the system. In particular, MRI 
may exert forces on the implanted material and therefore may 
induce the risk of, for example, intraspinal bleeding. Last 
year a MRI-compatible SCS system was newly introduced. 
However, a recent study showed that as with conventional 
SCS systems using an adapted protocol, a MRI (1.5 T) can 
be performed safely.124
Long-term outcomes  
and place in therapy
Outcomes of SCS therapy have considerably improved over 
the course of the last 30 years. Although in the 1970s about 
40% of the patients achieved pain relief of more than 50%, this 
percentage in recent studies is more than 70%. Proper patient 
selection and meticulous preoperative diagnostics, including 
psychological assessment, are crucial for the success of the 
method. Moreover, more knowledge regarding promising 
indications has been gathered over the course of the years. 
SCS therapy today is not necessarily seen as a therapy of last 
resort, but as an effective possibility to overcome pain that 
would otherwise be difficult to treat. Unsuccessful conven-
tional medical management is regarded as a criterion in favor 
of an SCS trial. However, most of the guidelines do not state 
whether or not opioids, particularly strong opioids, should be 
employed. Today, many pain physicians probably would not 
insist on a prior therapeutic attempt with highly potent opioids, 
and SCS would be ranked in the therapeutic order between 
weak and strong opioids. At any rate, the disadvantages of 
long-term opioid therapy125 should be weighed against those 
of SCS therapy. SCS can certainly be used together with anal-
getic medications, but in an optimal setting, SCS can make 
pain medication redundant. Often, however, patients continue 
to take analgetic medications. For instance, in a study on 
60 consecutive patients, 16% of the patients took no analgetics 
at all after SCS implantation, whereas more than half of the 
patients took two or more different analgetics.31
Another important point is the duration of conservative 
therapy before SCS implantation. Kumar et al observed 
an inverse correlation between the long-term success rate 
and the time interval between the onset of the chronic 
pain syndrome and SCS implantation. They noted that the 
success rate in patients who received their SCS system 
within the first 2 years of their pain syndrome was 85%, 
whereas the success rate was 9% in patients with a more 
than 15-year history of chronic pain.126,127 As a consequence, 
an SCS trial should be performed within the first 2 years 
Table 3 Possible complications of spinal cord stimulation
Complication
Hardware-related
    Lead migration 
Lead breakage 
Connection failure 
Battery depletion 
Unwanted paresthesia 
Pain at the impulse generator site
Not hardware-related
    Hematoma, seroma infection 
Cerebrospinal fluid loss 
Neurological deficitJournal of Pain Research 2014:7 submit your manuscript | www.dovepress.com
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after onset of pain. In contrast, also less invasive therapies 
should have been tried before an SCS trial, so realistically, 
SCS will rarely be applied earlier than 6–12 months from 
the onset of pain. Anyway, also a recent review concluded 
that SCS for CRPS “should be considered earlier than last 
resort therapy”.128
Conclusion
SCS is an effective treatment option for neuropathic pain. 
Technical advancement of SCS has led to improvement in 
stimulation patterns adapted to the patients’ needs. SCS for 
neuropathic pain is still underused. Careful preoperative 
diagnosis and proper patient selection is most important for 
the success of the methods.
Disclosure
The author reports no conflicts of interest in this work.
References
  1.  Freynhagen R, Baron R, Gockel U, Tölle TR. painDETECT: a 
new screening questionnaire to identify neuropathic components 
in patients with back pain. Curr Med Res Opin. 2006;22(10): 
1911–1920.
  2.  Finnerup NB, Otto M, McQuay HJ, Jensen TS, Sindrup SH. Algorithm 
for neuropathic pain treatment: an evidence based proposal. Pain. 
2005;118(3):289–305.
  3.  Kumar K, Rizvi S. Cost-effectiveness of spinal cord stimulation therapy 
in management of chronic pain. Pain Med. 2013;14(11):1631–1649.
  4.  Vyawahare B, Hallas N, Brookes M, Taylor RS, Eldabe S. Impact 
of the National Institute for Health and Care Excellence (NICE) 
guidance on medical technology uptake: analysis of the uptake of 
spinal cord stimulation in England 2008–2012. BMJ Open. 2014; 
4(1):e004182.
  5.  Melzack R, Wall PD. Pain mechanisms: a new theory. Science. 
1965;150(3699):971–979.
  6.  Shealy CN, Taslitz N, Mortimer JT, Becker DP. Electrical inhibi-
tion of pain: experimental evaluation. Anesth Analg. 1967;46(3): 
299–305.
  7.  Shealy CN, Mortimer JT, Reswick JB. Electrical inhibition of pain by 
stimulation of the dorsal columns: preliminary clinical report. Anesth 
Analg. 1967;46(4):489–491.
  8.  Shealy CN, Mortimer JT, Hagfors NR. Dorsal column electroanalgesia. 
J Neurosurg. 1970;32(5):560–564.
  9.  Nashold BS Jr, Friedman H. Dorsal column stimulation for control 
of pain. Preliminary report on 30 patients. J Neurosurg. 1972;36(5): 
590–597.
  10.  Hosobuchi Y, Adams JE, Weinstein PR. Preliminary percutaneous dorsal 
column stimulation prior to permanent implantation. Technical note.   
J Neurosurg. 1972;37(2):242–245.
  11.  Krainick JU, Thoden U. Experience with dorsal column stimula-
tion (DCS) in the operative treatment of chronic intractable pain. 
J Neurosurg Sci. 1974;18(3):187–189.
  12.  Tronnier V . [Neuromodulation for chronic pain conditions]. Bremen: 
Uni Med Verlag; 2003. German.
  13.  Grillo PJ, Yu HC, Patterson RH Jr. Delayed intraspinal hemorrhage 
after dorsal column stimulation for pain. Arch Neurol. 1974;30(1): 
105–106.
  14.  Taub A, Collins WF, Venes J. Partial, reversible, functional spinal cord 
transection. A complication of dorsal column stimulation for the relief 
of pain. Arch Neurol. 1974;30(1):107–108.
  15.  Nashold B, Somjen G, Friedman H. Paresthesias and EEG potentials 
evoked by stimulation of the dorsal funiculi in man. Exp Neurol. 
1972;36(2):273–287.
  16.  Barchini J, Tchachaghian S, Shamaa F, et al. Spinal segmental and 
supraspinal mechanisms underlying the pain-relieving effects of 
spinal cord stimulation: an experimental study in a rat model of 
neuropathy. Neuroscience. 2012;215:196–208.
  17.  Yakhnitsa V, Linderoth B, Meyerson BA. Spinal cord stimulation 
attenuates dorsal horn neuronal hyperexcitability in a rat model of 
mononeuropathy. Pain. 1999;79(2–3):223–233.
  18.  Stiller CO, Cui JG, O’Connor WT, Brodin E, Meyerson BA, Linderoth B.   
Release of gamma-aminobutyric acid in the dorsal horn and suppression 
of tactile allodynia by spinal cord stimulation in mononeuropathic rats. 
Neurosurgery. 1996;39(2):367–374.
  19.  Cui JG, O’Connor WT, Ungerstedt U, Linderoth B, Meyerson BA. Spinal 
cord stimulation attenuates augmented dorsal horn release of excitatory 
amino acids in mononeuropathy via a GABAergic mechanism. Pain. 
1997;73(1):87–95.
20.  Linderoth B, Meyerson BA. Spinal cord stimulation: exploration 
of the physiological basis of a widely used therapy. Anesthesiology. 
2010;113(6):1265–1267.
  21.  Cui JG, Linderoth B, Meyerson BA. Effects of spinal cord stimula-
tion on touch-evoked allodynia involve GABAergic mechanisms. An 
experimental study in the mononeuropathic rat. Pain. 1996;66(2–3): 
287–295.
  22.  Schechtmann G, Song Z, Ultenius C, Meyerson BA, Linderoth B. 
Cholinergic mechanisms involved in the pain relieving effect of spinal 
cord stimulation in a model of neuropathy. Pain. 2008;139(1):136–145.
  23.  Song Z, Meyerson BA, Linderoth B. Muscarinic receptor activation 
potentiates the effect of spinal cord stimulation on pain-related behavior 
in rats with mononeuropathy. Neurosci Lett. 2008;436(1):7–12.
  24.  Song Z, Ultenius C, Meyerson BA, Linderoth B. Pain relief by spinal cord 
stimulation involves serotonergic mechanisms: an experimental study 
in a rat model of mononeuropathy. Pain. 2009;147(1–3):241–248.
  25.  Saadé NE, Tabet MS, Soueidan SA, Bitar M, Atweh SF, Jabbur SJ. 
Supraspinal modulation of nociception in awake rats by stimulation of 
the dorsal column nuclei. Brain Res. 1986;369(1–2):307–310.
  26.  Saadé NE, Atweh SF, Privat A, Jabbur SJ. Inhibitory effects from various 
types of dorsal column and raphe magnus stimulations on nociceptive 
withdrawal flexion reflexes. Brain Res. 1999;846(1):72–86.
  27.  El-Khoury C, Hawwa N, Baliki M, Atweh SF, Jabbur SJ, Saadé NE.   
Attenuation of neuropathic pain by segmental and supraspinal 
  activation of the dorsal column system in awake rats. Neuroscience. 
2002;112(3):541–553.
  28.  Guan Y, Wacnik PW, Yang F, et al. Spinal cord stimulation-induced anal-
gesia: electrical stimulation of dorsal column and dorsal roots attenuates 
dorsal horn neuronal excitability in neuropathic rats. Anesthesiology. 
2010;113(6):1392–1405.
  29.  Kumar K, Wilson JR. Factors affecting spinal cord stimulation outcome 
in chronic benign pain with suggestions to improve success rate. Acta 
Neurochir Suppl. 2007;97(Pt 1):91–99.
30.  Sparkes E, Raphael JH, Duarte RV , LeMarchand K, Jackson C, Ashford RL.   
A systematic literature review of psychological characteristics as 
determinants of outcome for spinal cord stimulation therapy. Pain. 
2010;150(2):284–289.
  31.  Wolter T, Fauler I, Kieselbach K. The impact of psychological factors 
on outcomes for spinal cord stimulation: an analysis with long-term 
follow-up. Pain Physician. 2013;16(3):265–275.
  32.  Brandwin MA, Kewman DG. MMPI indicators of treatment response 
to spinal epidural stimulation in patients with chronic pain and patients 
with movement disorders. Psychol Rep. 1982;51(3 Pt 2):1059–1064.
  33.  Burchiel KJ, Anderson VC, Brown FD, et al. Prospective, multicenter 
study of spinal cord stimulation for relief of chronic back and extremity 
pain. Spine. 1996;21(23):2786–2794.
  34.  Wolter T, Winkelmüller M. Continuous versus intermittent spinal 
cord stimulation: an analysis of factors influencing clinical efficacy. 
Neuromodulation. 2012;15(1):13–19, discussion 20.Journal of Pain Research 2014:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
661
Spinal cord stimulation for neuropathic pain
  35.  De Ridder D, Vanneste S, Plazier M, van der Loo E, Menovsky T. Burst 
spinal cord stimulation: toward paresthesia-free pain suppression. 
Neurosurgery. 2010;66(5):986–990.
  36.  De Ridder D, Plazier M, Kamerling N, Menovsky T, Vanneste S. Burst 
spinal cord stimulation for limb and back pain. World Neurosurg. 
2013;80(5):642–649.
  37.  Van Buyten JP, Al-Kaisy A, Smet I, Palmisani S, Smith T. High-
frequency spinal cord stimulation for the treatment of chronic back 
pain patients: results of a prospective multicenter European clinical 
study. Neuromodulation. 2013;16(1):59–65.
  38.  Al-Kaisy A, Van Buyten JP, Smet I, Palmisani S, Pang D, Smith T. 
Sustained effectiveness of 10 kHz high-frequency spinal cord stimula-
tion for patients with chronic, low back pain: 24-month results of a 
prospective multicenter study. Pain Med. 2014;15(3):347–354.
  39.  Perruchoud C, Eldabe S, Batterham AM, et al. Analgesic efficacy of 
high-frequency spinal cord stimulation: a randomized double-blind 
placebo-controlled study. Neuromodulation. 2013;16(4):363–369, 
discussion 369.
  40.  Barolat G, Zeme S, Ketcik B. Multifactorial analysis of epidural spinal 
cord stimulation. Stereotact Funct Neurosurg. 1991;56(2):77–103.
  41.  Cameron T, Alo KM. Effects of posture on stimulation parameters in 
spinal cord stimulation. Neuromodulation. 1998;1(4):177–183.
  42.  Olin JC, Kidd DH, North RB. Postural changes in spinal cord stimula-
tion perceptual thresholds. Neuromodulation. 1998;1(4):171–175.
  43.  Holsheimer J, Barolat G, Struijk JJ, He J. Significance of the spinal 
cord position in spinal cord stimulation. Acta Neurochir Suppl (Wien). 
1995;64:119–124.
  44.  Abejon D, Feler CA. Is impedance a parameter to be taken into account 
in spinal cord stimulation? Pain Physician. 2007;10(4):533–540.
  45.  Holsheimer J, den Boer JA, Struijk JJ, Rozeboom AR. MR assessment 
of the normal position of the spinal cord in the spinal canal. AJNR Am 
J Neuroradiol. 1994;15(5):951–959.
  46.  Schade CM, Schultz DM, Tamayo N, Iyer S, Panken E. Automatic 
adaptation of neurostimulation therapy in response to changes in patient 
position: results of the Posture Responsive Spinal Cord Stimulation 
(PRS) Research Study. Pain Physician. 2011;14(5):407–417.
  47.  Schultz DM, Webster L, Kosek P, Dar U, Tan Y, Sun M. Sensor-
driven position-adaptive spinal cord stimulation for chronic pain.   
Pain Physician. 2012;15(1):1–12.
  48.  Law JD, Swett J, Kirsch WM. Retrospective analysis of 22 patients 
with chronic pain treated by peripheral nerve stimulation. J Neurosurg. 
1980;52(4):482485.
  49.  Buschmann D, Oppel F. [Peripheral nerve stimulation for pain 
relief in CRPS II and phantom-limb pain]. Schmerz. 1999;13(2): 
113–120. German.
  50.  Weiner RL, Reed KL. Peripheral neurostimulation for control of intrac-
table occipital neuralgia. Neuromodulation. 1999;2(3):217–221.
  51.  Burns B, Watkins L, Goadsby PJ. Treatment of medically intractable 
cluster headache by occipital nerve stimulation: long-term follow-up 
of eight patients. Lancet. 2007;369(9567):1099–1106.
  52.  Burns B, Watkins L, Goadsby PJ. Treatment of intractable chronic clus-
ter headache by occipital nerve stimulation in 14 patients. Neurology. 
2009;72(4):341–345.
  53.  Magis D, Allena M, Bolla M, De Pasqua V , Remacle JM, Schoenen J. 
Occipital nerve stimulation for drug-resistant chronic cluster headache: 
a prospective pilot study. Lancet Neurol. 2007;6(4):314–321.
  54.  Magis D, Gerardy PY, Remacle JM, Schoenen J. Sustained effective-
ness of occipital nerve stimulation in drug-resistant chronic cluster 
headache. Headache. 2011;51(8):1191–1201.
  55.  Tronnier V, Rasche D. [Subcutaneous peripheral stimulation of 
the greater occipital nerve for the treatment of chronic headache 
syndromes]. Schmerz. 2010;24(5):441–448. German.
  56.  Paicius RM, Bernstein CA, Lempert-Cohen C. Peripheral nerve field 
stimulation in chronic abdominal pain. Pain Physician. 2006;9(3): 
261–266.
  57.  Barolat G. Peripheral subcutaneous stimulation for intractable abdomi-
nal pain. Prog Neurol Surg. 2011;24:70–76.
  58.  McJunkin TL, Berardoni N, Lynch PJ, Amrani J. An innovative 
case report detailing the successful treatment of post-thoracotomy 
syndrome with peripheral nerve field stimulation. Neuromodulation. 
2010;13(4):311–314.
  59.  Goyal GN, Gupta D, Jain R, Kumar S, Mishra S, Bhatnagar S. Periph-
eral nerve field stimulation for intractable post-thoracotomy scar 
pain not relieved by conventional treatment. Pain Pract. 2010;10(4): 
366–369.
  60.  Paicius RM, Bernstein CA, Lempert-Cohen C. Peripheral Nerve Field 
Stimulation for the Treatment of Chronic Low Back Pain: Preliminary 
Results of Long-Term Follow-up: A Case Series. Neuromodulation. 
2007;10(3):279–290.
  61.  Bernstein CA, Paicius RM, Barkow SH, Lempert-Cohen C. Spinal cord 
stimulation in conjunction with peripheral nerve field stimulation for 
the treatment of low back and leg pain: a case series. Neuromodulation. 
2008;11(2):116–123.
  62.  Hamm-Faber TE, Aukes HA, de Loos F, Gültuna I. Subcutaneous 
stimulation as an additional therapy to spinal cord stimulation for 
the treatment of lower limb pain and/or back pain: a feasibility study. 
Neuromodulation. 2012;15(2):108–116.
  63. Burgher AH, Huntoon MA, Turley TW, Doust MW, Stearns LJ. 
Subcutaneous peripheral nerve stimulation with inter-lead stimula-
tion for axial neck and low back pain: case series and review of 
the literature. Neuromodulation. 2012;15(2):100–106, discussion 
106–107.
  64.  Yakovlev AE, Resch BE, Yakovleva VE. Peripheral nerve field 
stimulation in the treatment of postlaminectomy syndrome after 
multilevel spinal surgeries. Neuromodulation. 2011;14(6):534–538, 
discussion 538.
  65.  Reverberi C, Dario A, Barolat G. Spinal cord stimulation (SCS) in 
conjunction with peripheral nerve field stimulation (PNfS) for the 
treatment of complex pain in failed back surgery syndrome (FBSS). 
Neuromodulation. 2013;16(1):78–82.
  66.  Patil AA, Otto D, Raikar S. Peripheral nerve field stimulation for sac-
roiliac joint pain. Neuromodulation. 2014;17(1):98–101.
  67.  Lepski G, Vahedi P, Tatagiba MS, Morgalla M. Combined spi-
nal cord and peripheral nerve field stimulation for persistent 
post-herniorrhaphy pain. Neuromodulation. 2013;16(1):84–88,   
discussion 88–89.
  68.  Verrills P, Vivian D, Mitchell B, Barnard A. Peripheral nerve field 
stimulation for chronic pain: 100 cases and review of the literature. Pain 
Med. 2011;12(9):1395–1405.
  69.  Sator-Katzenschlager S, Fiala K, Kress HG, et al. Subcutaneous target 
stimulation (STS) in chronic noncancer pain: a nationwide retrospective 
study. Pain Pract. 2010;10(4):279–286.
  70.  Kloimstein H, Likar R, Kern M, et al. Peripheral nerve field stimula-
tion (PNFS) in chronic low back pain: a prospective multicenter study. 
Neuromodulation. 2014;17(2):180–187.
  71.  Goroszeniuk T, Kothari S, Hamann W. Subcutaneous neuromodu-
lating implant targeted at the site of pain. Reg Anesth Pain Med. 
2006;31(2):168–171.
  72.  Falco FJ, Berger J, Vrable A, Onyewu O, Zhu J. Cross talk: a new method 
for peripheral nerve stimulation. An observational report with cadaveric 
verification. Pain Physician. 2009;12(6):965–983.
  73.  Mironer YE, Hutcheson JK, Satterthwaite JR, LaTourette PC. 
Prospective, two-part study of the interaction between spinal 
cord stimulation and peripheral nerve field stimulation in patients 
with low back pain: development of a new spinal-peripheral neu-
rostimulation method. Neuromodulation. 2011;14(2):151–154,   
discussion 155.
  74.  Lipov EG. ‘Hybrid neurostimulator’: simultaneous use of spinal 
cord and peripheral nerve field stimulation to treat low back and leg 
pain. Prog Neurol Surg. 2011;24:147–155.
  75.  McRoberts WP, Wolkowitz R, Meyer DJ, et al. Peripheral nerve field 
stimulation for the management of localized chronic intractable back 
pain: results from a randomized controlled study. Neuromodulation. 
2013;16(6):565–574, discussion 574–575.Journal of Pain Research 2014:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
662
wolter
  76.  Wolter T, Kieselbach K, Sircar R, Gierthmuehlen M. Spinal cord stimu-
lation inhibits cortical somatosensory evoked potentials significantly 
stronger than transcutaneous electrical nerve stimulation. Pain Physi-
cian. 2013;16(4):405–414.
  77.  Deer TR, Grigsby E, Weiner RL, Wilcosky B, Kramer JM. A prospec-
tive study of dorsal root ganglion stimulation for the relief of chronic 
pain. Neuromodulation. 2013;16(1):67–71, discussion 71–72.
  78.  Liem L, Russo M, Huygen FJ, et al. A multicenter, prospective trial 
to assess the safety and performance of the spinal modulation dorsal 
root ganglion neurostimulator system in the treatment of chronic pain. 
Neuromodulation. 2013;16(5):471–482, discussion 482.
  79.  Van Buyten JP, Smet I, Liem L, Russo M, Huygen F. Stimulation of 
Dorsal Root Ganglia for the Management of Complex Regional Pain 
Syndrome: A Prospective Case Series. Pain Pract. Jan 2014:23.
  80.  van Buyten JP, Linderoth B. “The failed back surgery syndrome’: 
Definition and therapeutic algorithms – An update.” Eur J Pain 
Suppl. 2010;4(4):273–286.
  81.  North RB, Kidd DH, Farrokhi F, Piantadosi SA. Spinal cord stimulation 
versus repeated lumbosacral spine surgery for chronic pain: a random-
ized, controlled trial. Neurosurgery. 2005;56(1):98–106, discussion 
106–107.
  82.  Kumar K, North R, Taylor R, et al. Spinal Cord Stimulation vs 
Conventional Medical Management: A Prospective, Randomized,   
Controlled, Multicenter Study of Patients with Failed Back Surgery 
Syndrome (PROCESS Study). Neuromodulation. 2005;8(4): 
213–218.
  83.  Frey ME, Manchikanti L, Benyamin RM, Schultz DM, Smith HS,   
Cohen SP. Spinal cord stimulation for patients with failed back sur-
gery syndrome: a systematic review. Pain Physician. 2009;12(2): 
379–397.
  84.  Kemler MA, De Vet HC, Barendse GA, Van Den Wildenberg FA, Van 
Kleef M. The effect of spinal cord stimulation in patients with chronic 
reflex sympathetic dystrophy: two years’ follow-up of the randomized 
controlled trial. Ann Neurol. 2004;55(1):13–18.
  85.  Kemler MA, de Vet HC, Barendse GA, van den Wildenberg FA, 
van Kleef M. Spinal cord stimulation for chronic reflex sympathetic 
dystrophy – five-year follow-up. N Engl J Med. 2006;354(22): 
2394–2396.
  86.  Kemler MA, de Vet HC, Barendse GA, van den Wildenberg FA, van 
Kleef M. Effect of spinal cord stimulation for chronic complex regional 
pain syndrome Type I: five-year final follow-up of patients in a random-
ized controlled trial. J Neurosurg. 2008;108(2):292–298.
  87.  Harke H, Gretenkort P, Ladleif HU, Rahman S. Spinal cord stimula-
tion in sympathetically maintained complex regional pain syndrome 
type I with severe disability. A prospective clinical study. Eur J Pain. 
2005;9(4):363–373.
  88.  Taylor RS. Spinal cord stimulation in complex regional pain syndrome 
and refractory neuropathic back and leg pain/failed back surgery syn-
drome: results of a systematic review and meta-analysis. J Pain Symptom 
Manage. 2006;31(4)(Suppl):S13–S19.
  89.  Harke H, Gretenkort P, Ladleif HU, Koester P, Rahman S. Spinal 
cord stimulation in postherpetic neuralgia and in acute herpes zoster 
pain. Anesth Analg. 2002;94(3):694–700. Table of contents.
  90.  Meglio M, Cioni B, Rossi GF. Spinal cord stimulation in manage-
ment of chronic pain. A 9-year experience. J Neurosurg. 1989;70(4): 
519–524.
  91.  Broggi G, Servello D, Dones I, Carbone G. Italian multicentric study on 
pain treatment with epidural spinal cord stimulation. Stereotact Funct 
Neurosurg. 1994;62(1–4):273–278.
  92.  Kumar K, Toth C, Nath RK. Spinal cord stimulation for chronic pain 
in peripheral neuropathy. Surg Neurol. 1996;46(4):363–369.
  93.  Cameron T. Safety and efficacy of spinal cord stimulation for the 
treatment of chronic pain: a 20-year literature review. J Neurosurg. 
2004;100(Suppl Spine 3):254–267.
  94.  Moriyama K. Effect of temporary spinal cord stimulation on pos-
therpetic neuralgia in the thoracic nerve area. Neuromodulation. 
2009;12(1):39–43.
  95.  Iseki M, Morita Y, Nakamura Y, Ifuku M, Komatsu S. Efficacy of 
limited-duration spinal cord stimulation for subacute postherpetic 
neuralgia. Ann Acad Med Singapore. 2009;38(11):1004–1006.
  96.  Tesfaye S, Watt J, Benbow SJ, Pang KA, Miles J, MacFarlane IA. 
Electrical spinal-cord stimulation for painful diabetic peripheral 
  neuropathy. Lancet. 1996;348(9043):1698–1701.
  97.  Pluijms WA, Slangen R, Joosten EA, et al. Electrical spinal cord stimu-
lation in painful diabetic polyneuropathy, a systematic review 
on treatment efficacy and safety. Eur J Pain. 2011;15(8): 783–788.
  98.  Slangen R, Pluijms WA, Faber CG, Dirksen CD, Kessels AG, van 
Kleef M. Sustained effect of spinal cord stimulation on pain and 
quality of life in painful diabetic peripheral neuropathy. Br J Anaesth. 
2013;111(6):1030–1031.
  99.  Campos WK, Almeida de Oliveira  YS, Ciampi de Andrade D, Teixeira MJ,   
Fonoff ET. Spinal cord stimulation for the treatment of neuropathic 
pain related to syringomyelia. Pain Med. 2013;14(5):767–768.
  100.  Wininger KL, Bester ML, Deshpande KK. Spinal cord stimulation to 
treat postthoracotomy neuralgia: non-small-cell lung cancer: a case 
report. Pain Manag Nurs. 2012;13(1):52–59.
  101.  Messina G, Nazzi V , Sinisi M, Dones I, Pollo B, Franzini A. Spinal 
cord stimulation for recurrent painful neuromas of the foot. Neurol 
Sci. 2011;32(4):723–725.
  102.  Moens M, De Smedt A, D’Haese J, Droogmans S, Chaskis C. 
Spinal cord stimulation as a treatment for refractory neuropathic 
pain in tethered cord syndrome: a case report. J Med Case Reports. 
2010;4(1):74.
  103.  Barna SA, Hu MM, Buxo C, Trella J, Cosgrove GR. Spinal cord 
stimulation for treatment of meralgia paresthetica. Pain Physician. 
2005;8(3):315–318.
  104.  Burkey AR, Abla-Yao S. Successful treatment of central pain in a 
multiple sclerosis patient with epidural stimulation of the dorsal root 
entry zone. Pain Med. 2010;11(1):127–132.
  105.  Williams KA, Babade M, Cohen SP. Spinal cord stimulation for severe 
degenerative joint disease of the shoulder in a patient with severe 
chronic obstructive pulmonary disease: a new indication? Anesth 
Analg. 2010;110(1):220–221.
  106.  Lowry AM, Simopoulos TT. Spinal cord stimulation for the treatment 
of chronic knee pain following total knee replacement. Pain Physician. 
2010;13(3):251–256.
  107.  Kumar K, Taylor RS, Jacques L, et al. Spinal cord stimulation versus 
conventional medical management for neuropathic pain: a multicentre 
randomised controlled trial in patients with failed back surgery 
syndrome. Pain. 2007;132(1–2):179–188.
  108.  North RB, Kidd DH, Lee MS, Piantodosi S. A prospective, random-
ized study of spinal cord stimulation versus reoperation for failed 
back surgery syndrome: initial results. Stereotact Funct Neurosurg. 
1994;62(1–4):267–272.
  109.  North RB, Kidd DH, Piantadosi S. Spinal cord stimulation ver-
sus reoperation for failed back surgery syndrome: a prospective, 
randomized study design. Acta Neurochir Suppl (Wien). 1995;64: 
106–108.
  110.  Kemler MA, Barendse GA, van Kleef M, et al. Spinal cord stimulation 
in patients with chronic reflex sympathetic dystrophy. N Engl J Med. 
2000;343(9):618–624.
  111.  Wolter T, Kiemen A, Porzelius C, Kaube H. Effects of sub-
perception threshold spinal cord stimulation in neuropathic pain: 
a randomized controlled double-blind crossover study. Eur J Pain. 
2012;16(5):648–655.
  112.  Smith CC, Lin JL, Shokat M, Dosanjh SS, Casthely D. A report of 
paraparesis following spinal cord stimulator trial, implantation and 
revision. Pain Physician. 2010;13(4):357–363.
  113.  Meyer SC, Swartz K, Johnson JP. Quadriparesis and spinal cord 
stimulation: case report. Spine. 2007;32(19):E565–E568.
  114.  Barolat G, Peacock W, Staudt L. Pain and spasticity. In: Benzel E,   
editor. Spine Surgery: Techniques, Complication Avoidance, and 
Management. Vol 2. 2nd ed. Philadelphia: Elsevier Churchill 
Livingstone; 2005:1239–1252.Journal of Pain Research
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/journal-of-pain-research-journal
The Journal of Pain Research is an international, peer-reviewed, open 
access, online journal that welcomes laboratory and clinical findings 
in the fields of pain research and the prevention and management 
of pain. Original research, reviews, symposium reports, hypoth-
esis formation and commentaries are all considered for publication.   
The manuscript management system is completely online and includes 
a very quick and fair peer-review system, which is all easy to use. Visit 
http://www.dovepress.com/testimonials.php to read real quotes from 
published authors.
Journal of Pain Research 2014:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
663
Spinal cord stimulation for neuropathic pain
  115.  Dam-Hieu P, Magro E, Seizeur R, Simon A, Quinio B. Cervical cord 
compression due to delayed scarring around epidural electrodes 
used in spinal cord stimulation. J Neurosurg Spine. 2010;12(4): 
409–412.
  116.  Wada E, Kawai H. Late onset cervical myelopathy secondary to fibrous 
scar tissue formation around the spinal cord stimulation electrode. 
Spinal Cord. 2010;48(8):646–648.
  117.  Cicuendez M, Munarriz PM, Castaño-Leon AM, Paredes I.   Dorsal 
myelopathy secondary to epidural fibrous scar tissue around a 
spinal cord stimulation electrode. J Neurosurg Spine. 2012;17(6): 
598–601.
  118. Wloch A, Capelle HH, Saryyeva A, Krauss JK. Cervical myel-
opathy due to an epidural cervical mass after chronic cervical 
spinal cord stimulation. Stereotact Funct Neurosurg. 2013;91(4): 
265–269.
  119.  Lennarson PJ, Guillen FT. Spinal cord compression from a foreign 
body reaction to spinal cord stimulation: a previously unreported 
complication. Spine. 2010;35(25):E1516–E1519.
  120.  Taylor RS, Van Buyten JP, Buchser E. Spinal cord stimulation for 
chronic back and leg pain and failed back surgery syndrome: a sys-
tematic review and analysis of prognostic factors. Spine (Phila Pa 
1976). 2005;30(1):152–160.
  121.  Mekhail NA, Mathews M, Nageeb F, Guirguis M, Mekhail MN, 
Cheng J. Retrospective review of 707 cases of spinal cord stimulation: 
indications and complications. Pain Pract. 2011;11(2):148–153.
  122.  Rosenow JM, Stanton-Hicks M, Rezai AR, Henderson JM. Failure 
modes of spinal cord stimulation hardware. J Neurosurg Spine. 
2006;5(3):183–190.
  123.  Babu R, Hazzard MA, Huang KT, et al. Outcomes of percutaneous 
and paddle lead implantation for spinal cord stimulation: a com-
parative analysis of complications, reoperation rates, and health-care 
costs. Neuromodulation. 2013;16(5):418–426, discussion 426–427.
  124.  Mutter UM, Bellut D, Porchet F, Schuknecht B. Spinal magnetic 
resonance imaging with reduced specific absorption rate in patients 
harbouring a spinal cord stimulation device – A single-centre pro-
spective study analysing safety, tolerability and image quality. Acta 
Neurochir (Wien). 2013;155(12):2327–2332.
  125.  Ivanova JI, Birnbaum HG, Yushkina Y, Sorg RA, Reed J, Merchant S.   
The prevalence and economic impact of prescription opioid-related 
side effects among patients with chronic noncancer pain. J Opioid 
Manag. 2013;9(4):239–254.
  126.  Kumar K, Hunter G, Demeria D. Spinal cord stimulation in treatment 
of chronic benign pain: challenges in treatment planning and present 
status, a 22-year experience. Neurosurgery. 2006;58(3):481–496, 
discussion 481–496.
  127.  Kumar K, Rizvi S, Nguyen R, Abbas M, Bishop S, Murthy V . Impact 
of Wait times on Spinal Cord Stimulation Therapy Outcomes. Pain 
Pract. Epub October 25, 2013.
  128.  Poree L, Krames E, Pope J, Deer TR, Levy R, Schultz L. Spinal cord 
stimulation as treatment for complex regional pain syndrome should 
be considered earlier than last resort therapy. Neuromodulation. 
2013;16(2):125–141.